OpGen (NASDAQ:OPGN) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a research report issued on Tuesday. The firm set a “sell” rating on the medical research company’s stock.

OpGen Trading Up 19.3 %

Shares of NASDAQ OPGN opened at $3.22 on Tuesday. OpGen has a 1 year low of $0.53 and a 1 year high of $8.40. The company’s 50-day moving average is $1.37 and its 200 day moving average is $1.46.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.